98%
921
2 minutes
20
The Specialized Center of Research Excellence (SCORE) on sex differences at University of California, Los Angeles (UCLA) has a long track record studying bidirectional interactions between different organs and the brain in health and disease with a strong focus on sex as a biological variable (SABV). While the initial focus was on brain-gut interactions in irritable bowel syndrome (IBS), one of the most common disorders of gut-brain interaction, the scope of our Center's research has expanded to a range of different diseases, including inflammatory bowel disease, alcohol use disorder, obesity, urological chronic pelvic pain syndrome, and vulvodynia. This expansion of research focused on the role of brain-body and brain-gut microbiome interactions in these various disorders, aligning well with the increasing importance of multidisciplinary and interdisciplinary team science. The SCORE's Career Enhancement Core (CEC) has modeled team science as applied to SABV research, with educational and training opportunities, a mentoring program, seed grant funding, and other career development experiences that enable mentees to work across the disciplines involved in brain body research. The CEC goals are: (1) To provide seed grant funds for innovative research relevant to the overall SCORE mission and research program; (2) to recruit and foster the career development of students, trainees, and junior investigators who conduct research focused on sex differences or women's health in IBS and chronic constipation and other brain-gut disorders; (3) to facilitate and promote collaboration between the UCLA SCORE and other academic programs involved in women's health education and research; and (4) to promote the importance of SABV through community outreach using collaborative and innovative approaches. These goals focus on establishing the leading research center in sex differences in basic, translational, and clinical aspects of brain-body interactions and on providing women and underrepresented individuals with research opportunities needed to become independent investigators.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457633 | PMC |
http://dx.doi.org/10.1089/jwh.2022.0504 | DOI Listing |
Hormones (Athens)
September 2025
Department of Urology, Yueqing People's Hospital, No.338 Qingyuan Road, Yueqing, Zhejiang, 325600, China.
Objective: This study aimed to evaluate the efficacy of combining levocarnitine with tadalafil in treating oligozoospermia and asthenozoospermia and to analyze its effects on serum sex hormone levels and sexual function.
Methods: A total of 80 patients diagnosed with oligozoospermia or asthenozoospermia at our hospital between March 2023 and February 2024 were randomly divided into two groups, A and B, with 40 patients each. Group A received levocarnitine combined with tadalafil, while Group B was administered levocarnitine alone.
Qual Life Res
September 2025
Department of Epidemiology, School of Public Health, Cheeloo College of Medicine, Shandong University, 44 West Wenhua Road, Jinan, 250012, Shandong, China.
Purpose: The study aimed to assess the interconnection of quality of life (QoL) variables and identify key areas for which interventions could improve QoL among men who have sex with men (MSM) living with HIV on antiretroviral therapy (ART).
Methods: A cross-sectional study was conducted in Jinan of Shandong Province, between October to December 2020. Undirected network analyses were conducted to examine and visualize the interconnections between QoL variables among MSM living with HIV.
Ann Surg Oncol
September 2025
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Background: The optimal number of examined lymph nodes (ELN) for accurate staging and prognosis for esophageal cancer patients receiving neoadjuvant therapy remains controversial. This study aimed to evaluate the impact of ELN count on pathologic staging and survival outcomes and to develop a predictive model for lymph node positivity in this patient population.
Methods: Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database and a multicenter cohort.
Ned Tijdschr Geneeskd
September 2025
UMC Utrecht, afd. huisartsgeneeskunde, Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde, Utrecht.
Objective: To investigate sex differences in the pharmacological treatment of hypertension in primary care.
Design: Cross-sectional study among 14,384 patients with hypertension from the Julius General Practitioners' Network, without cardiovascular disease or diabetes, treated with antihypertensive medications.
Methods: We compared men and women in the number and type of prescribed antihypertensives and their blood pressure.
IISE Trans Occup Ergon Hum Factors
September 2025
Department of Industrial and Systems Engineering, Virginia Tech, Blacksburg, Virginia, USA.
Occupational ApplicationsWe investigated the effects of age and sex on cybersickness susceptibility during Virtual Reality (VR)-based forklift training, using an order picker forklift truck consisting of basic and common forklift driving scenarios. Cybersickness occurrence was assessed using the Simulator Sickness Questionnaire (SSQ) and analyzed with the survival analysis method. Our analysis indicated strong vulnerability among older adults yet no significant influence of biological sex on cybersickness susceptibility.
View Article and Find Full Text PDF